GSK vs. Gilead in AIDS treatment race

Jun 22, 2018

GlaxoSmithKline and Gilead Sciences will be showcasing rival strategies for fighting the AIDS virus at next month’s global AIDS conference.

ViiV Healthcare, a joint effort between GSK and Pfizer, will be presenting detailed trial results from its new two-drug treatment combining dolutegravir (Tivicay) and lamivudine (Epivir), after announcing last week that the studies met primary endpoints.

Gilead, currently with an AIDS market share of 52 percent versus GSK’s 22 percent, will stick with the industry standard three-drug combinations. Gilead’s Biktarvy, a triple-therapy, single-tablet drug to treat HIV, was cleared for sale in the U.S. in February. A month later, Gilead released data from a head-to-head clinical trial showing that Biktarvy is noninferior to a treatment containing Tivicay and Epivir, plus another ViiV drug, Ziagen.

Read the Reuters coverage 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments